However, the J2H-1702-treated group had significantly decreased ALT and AST levels compared with the NASH group, suggesting that NASH-induced livers were somewhat protected when treated with J2H-1702 (Fig. 4B). This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.